drugset / Trial / NCT00709371

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

NCT00709371 ↗

Phase 2 Completed 729 enrolled Orexigen Therapeutics, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.

Timeline

Start
2008-07
Primary completion
2009-04
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule 360 mg —
Comparator Zonisamide Other / unclassified 120 mg —
Comparator Zonisamide Other / unclassified 360 mg —

Indications